Psoriasis Revolution

Psoriasis Homeopathic Remedies

Get Instant Access

1. Franssen MJAM, van den Hoogen FHJ, van de Putte LBA. Psoriatic Arthropathy. In: van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell Science, 1999:30-42.

2. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39-42.

3. van de Kerkhof PCM. Clinical features. In: van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell Science, 1999:3-29.

4. Farber EM, Nall L. Epidemiology: natural history and genetics. In: Roenigk HH, Maibach HI, eds. Psoriasis, 3rd ed. New York: Marcel Dekker, 1998:107-57.

5. Camp RDR. Psoriasis. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology, 6th edn. Oxford: Blackwell Science, 1998:1589-1649.

6. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996;135:533-7.

7. van de Kerkhof PCM. Pathogenesis. In: van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell Science, 1999:79-105.

8. Savin JA. Psychosocial Aspects. In: van de Kerkhof PCM, ed. Textbook of Psoriasis. Oxford: Blackwell Science, 1999:43-53.

9. Martin BA, Chalmers RJ, Telfer NR. How great is the risk of further psoriasis following a single episode of acute guttate psoriasis? Arch Dermatol 1996;132:717-18.

10. Optimal search strategy for RCTs. From Dickersin K, Larson K. Establishing and maintaining an international register of RCTs. In: Cochrane Collaboration. Cochrane Library Oxford: Update Software, 1996.

11. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4(40):1-115.

12. Watsky KL, Freije L, Leneveu MC, Wenck HA, Leffell DJ. Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis. Cutis 1992;50:383-6.

13. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996;76: 353-6.

14. Fredriksson TLM. A blind controlled comparison between a new cream ("12 + 12"), its vehicle, and salicylic acid in petrolatum on psoriatic plaques. Curr Ther Res 1985;37:805-9.

15. Friedman SJ. Management of psoriasis vulgaris with a hydrocolloid occlusive dressing. Arch Dermatol 1987;123:1046-52.

16. David M, Lowe NJ. Psoriasis therapy: comparative studies with a hydrocolloid dressing, plastic film occlusion, and triamcinolone acetonide cream. J Am Acad Dermatol 1989;21:511-14.

17. Nielsen PG. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of nummular psoriasis. Acta Derm Venereol 1993;73:394.

18. Koo J, Cuffie CA, Tanner DJ etal. Mometasone furoate 0-1%-salicylic acid 5% ointment versus mometasone furoate 0-1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998;20:283-91.

19. Zgrzyblowski A, Paradecki W, Przybyla L. Serum levels of salicylic acid in patients with psoriasis treated with 10% salicylic acid ointment. Przeglad Dermatol 1990;77:20-4.

20. Maune S, Frese KA, Mrowietz U, Reker U. Toxic inner ear damage in topical treatment of psoriasis with salicylates. Laryngorhinootologie 1997; 76:368-70.

21. Kristensen B, Kristensen O. Topical salicylic acid interferes with UVB therapy for psoriasis. Acta Derm Venereol 1991;71:37-40.

22. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-7.

23. Kragballe K, Barnes L, Hamberg KJ et al. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998;139:649-54.

24. Douglas WS, Bibby AJ. A new calcipotriol/ betamethasone formulation with rapid onset of action is superior to betamethasone dipropionate ointment and calcipotriol ointment in psoriasis. In: Congress abstracts from European Academy of Dermatology and Venereology 10th Congress. Munich: EADV, 2001:620.

25. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. Phototherapy and photochemotherapy. In: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4(40):55-74.

26. Gambichler T, Kreuter JA, Altmeyer P, Hoffmann K. Metaanalysis of the efficacy of balneophototherapy. Aktuelle Dermatol 2000;26:402-6.

27. Markham T, Rogers S, Collins P. A comparison of oral 8-methoxypsoralen PUVA and narrowband UVB (TL-01) phototherapy in the management of chronic plaque psoriasis. Br J Dermatol 2001;145(Suppl. 59):12-26.

28. Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999; 141: 497-501.

29. Frentz G, Olsen JH, Avrach WW. Malignant tumours and psoriasis: climatotherapy at the Dead Sea. Br J Dermatol 1999;141:1088-91.

30. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998;134:1582-5.

31. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001;44: 755-61.

32. British Photodermatology Group . British Photodermatology Group guidelines for PUVA. Br J Dermatol 1994;130: 246-55.

33. British Photodermatology Group. An appraisal of narrowband (TL-01) UVB phototherapy. British Photodermatology Group Workshop report (April 1996). Br J Dermatol 1997;137:327-30'

34. Boer J, Hermans J, Schothorst AA, Suurmond D. Comparison of phototherapy (UV-B) and photochemo-therapy (PUVA) for clearing and maintenance therapy of psoriasis. Arch Dermatol 1984;120:52-7.

35. Stern RS, Armstrong RB, Anderson TF et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol 1986; 15:546-52.

36. Adrian RM, Parrish JA, Khosrow M, Karlin MJ. Outpatient phototherapy for psoriasis. Arch Dermatol 1981;117:623-6.

37. Selvaag E, Caspersen L, Bech-Thomsen N, de Fine Olivarius F, Wulf HC. Optimized UVB treatment of psoriasis: a controlled, left-right comparison trial. J Eur Acad Dermatol Venereol 2000; 14:19-21.

38. van Weelden H, Baaart de la Faille H, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988;119:11-19.

39. Dawe RS, Wainwright NJ, Cameron H, Ferguson J. Narrow-band (TL-01) ultraviolet B phototherapy for chronic plaque psoriasis: three times or five times weekly treatment? Br J Dermatol 1998;138:833-839.

40. Snellman E, Aromaa A, Jansen CT et al. Supervised four-week heliotherapy alleviates the long-term course of psoriasis. Acta Derm Venereol 1993;73:388-92.

41. Löaute-Labräze C, Saillour F, Chane G et al. Saline spa water or combined water and UVB for psoriasis versus conventional UVB. Lessons from the Salies de Böarn randomized study. Arch Dermatol 2001;137:1035-9.

42. Turner RJ, Walshaw D, Diffey BL, Farr PM. A controlled study of ultraviolet A sunbed treatment of psoriasis. Br J Dermatol 2000; 143:957-63.

43. Melski JW, Tanenbaum L, Parrish JA et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68:328-35.

44. Henseler T, Wolff K, Honigsmann H, Christophers E. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1981;1:853-7.

45. de Berker DA, Sakuntabhai A, Diffey BL, Matthews JN, Farr PM. Comparison of psoralen-UVB and psoralen-UVA photochemotherapy in the treatment of psoriasis. J Am Acad Dermatol 1997;36:577-81.

46. Rogers S, Marks J, Shuster S, Briffa DV, Warin A, Greaves M. Comparison of photochemotherapy and dithranol in the treatment of chronic plaque psoriasis. Lancet 1979;1:455-8.

47. Collins P, Rogers S. Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. Br J Dermatol 1992;127:392-5.

48. Turjanmaa K, Salo H, Reunala T. Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis. Acta Derm Venereol 1985;65:86-8.

49. Cooper EJ, Herd RM, Priestley GC, Hunter JA. A comparison of bathwater and oral delivery of 8-methoxypsoralen in PUVA therapy for plaque psoriasis. Clin Exp Dermatol 2000;25:111-14.

50. Sadananda Naik PV, Paily PP, Gopinatha Pillai KG, Asokan PU. Photochemotherapy for psoriasis with psoralen and sunlight. Indian J Dermatol Venereol Lepr 1981;47:9-16.

51. Parrish JA, White AD, Kingsbury T, Zahar M, Fitzpatrick TB. Photochemotherapy of psoriasis using methoxsalen and sunlight. A controlled study. Arch Dermatol 1977; 113: 1529-32.

52. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999;41:728-32.

53. Dawe RS, Cameron H, Yule S et al. A comparison of TL-01 UVB phototherapy and bath-PUVA for chronic plaque psoriasis. Br J Dermatol 2000;143(Suppl. 57):15.

54. Lauharanta J, Juvakoski T, Lassus A. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol 1981;104:325-32.

55. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology 2000;200:17-24.

56. Brands S, Brakman M, Bos JD, de Rie MA. No additional effect of calcipotriol ointment on low-dose narrow-band UVB phototherapy in psoriasis. J Am Acad Dermatol 1999;41:991-5.

57. Gerritsen MJ, Boezeman JB, Elbers ME, van de Kerkhof PC. Dithranol embedded in crystalline monoglycerides combined with phototherapy (UVB): a new approach in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998;11:133-9.

58. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998;90:1278-84.

59. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. Cyclosporin. In: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4(40):13-23.

60. Laburte C, Grossman R, Abi-Rached J, Abeywickrama KH, Dubertret L. Efficacy and safety of oral cyclosporin A (CyA;Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130:366-75.

61. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis: Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995;131:791-5.

62. Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997;36:423-32.

63. Zachariae H, Abrams B, Bleehen SS et al. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability. Dermatology 1998;196:231-6.

64. Finzi AF, Mozzanica N, Pigatto PD et al. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Dermatology 1993;187:8-18.

65. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88.

66. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-9.

67. Powles AV, Hardman CM, Porter WM, Cook T, Hulme B, Fry L. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol 1998;138:443-9.

68. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. Oral retinoids. In: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4(40):25-49.

69. Ruzicka T, Sommerburg C, Braun-Falco O et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol 1990;126:482-6.

70. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-4.

71. Green C, Lakshmipathi T, Johnson BE, Ferguson J. A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy v. etretinate (re-TL-01) v. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. Br J Dermatol 1992;127:5-9.

72. Giannetti A, Coppini M, Bertazzoni MG et al. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis. J Eur Acad Dermatol Venereol 1999;13:91-5.

73. van de Kerkhof PC, Cambazard F, Hutchinson PE et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol 1998;138:84-9.

74. Danno K, Sugie N. Combination therapy with low-dose etretinate and eicosapentaenoic acid for psoriasis vulgaris. J Dermatol 1998;25:703-5.

75. Ashley JM, Lowe NJ, Borok ME, Alfin-Slater RB. Fish oil supplementation results in decreased hypertriglyceridemia in patients with psoriasis undergoing etretinate or acitretin therapy. J Am Acad Dermatol 1988;19:76-82.

76. Roenigk HH Jr, Callen JP, Guzzo CA et al. Effects of acitretin on the liver. J Am Acad Dermatol 1999;41:584-8.

77. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, Baughman RD. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 1995;33:44-52.

78. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. Methotrexate. In: A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4(40):51-3.

79. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis (Cochrane Review). In: Cochrane Collaboration. Cochrane Library Issue 4. Oxford: Update Software, 2001.

80. Van Dooren-Greebe RJ, Kuijpers ALA, Mulder J, De Boo T, Van de Kerkhof PCM. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994;130:204-10.

81. Zachariae H. Methotrexate in psoriasis. In: Burgdorf WHC, Katz SI, eds. Proceedings of the 18th World Congress of Dermatology. New York: Parthenon Publishing Group Inc., 1992:685-7.

82. van de Kerkhof PC, Mali JW. Methotrexate maintenance following Ingram therapy in "difficult" psoriasis. Br J Dermatol 1982;106:623-7.

83. Heydendael VMR, Spuls PI, Opmeer BC et al. Effectiveness, safety and quality of life of methotrexate versus cyclosporine A in moderate to severe psoriasis: a randomised controlled trial. Br J Dermatol 2002; 147: 1047-8.

84. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996;21:399-408.

85. Hanrahan E, Barnes L. Elevated serum homocysteine levels in patients with psoriasis receiving long-term, low-dose methotrexate therapy. Br J Dermatol 2001; 145 (Suppl. 59):43.

86. Rosenthal D, Guenther L, Kelly J. Current thoughts on the use of methotrexate in patients with psoriasis. J Cutan Med Surg 1997;2:41-6.

87. Nyfors A, Brodthagen H. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica 1970;140:345-55.

88. Weinstein GD, Roenigk H, Maibach M, Cosmides J, Halprin K, Millard M. Psoriasis-liver methotrexate interactions. Arch Dermatol 1973;108:36-42.

89. Weinstein GD, Frost P. Methotrexate for psoriasis - a new therapeutic schedule. Arch Dermatol 1971;103:33-8.

90. Zanolli MD, Sherertz EF, Hedberg AE. Methotrexate: anti-infammatory or antiproliferative? J Am Acad Dermatol 1990;22:523-4.

91. Boffa MJ, Chalmers RJG, Haboubi NY, Shomaf M, Mitchell DM. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995;133:774-8.

92. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol 1998;38:478-85.

93. Boffa MJ, Smith A, Chalmers RJG et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996;135:538-44.

94. Zachariae H, Heickendorff L, Soegaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001;143:100-3.

95. Leavell UW, Yarbro JW. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol 1970;102:144-50.

96. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1990;22:311-12.

97. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients [see comments]. J Am Acad Dermatol 1994;30:977-81.

98. Nieboer C, de Hoop D, van Loenen AC, Langendijk PN, van Dijk E. Systemic therapy with fumaric acid derivates: new possibilities in the treatment of psoriasis. J Am Acad Dermatol 1989;20:601-8.

99. Nieboer C, de Hoop D, Langendijk PN, van Loenen AC, Gubbels J. Fumaric acid therapy in psoriasis: a doubleblind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990;181:33-7.

100. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138:456-60.

101. du Vivier A, Munro DD, Verbov J. Azathioprine in psoriasis. BMJ 1974;1:49-51.

102. Gupta AK, Ellis CN, Siegel MT et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol 1990;126:487-93.

103. Owen CM, Chalmers RJ, O'Sullivan T, Griffiths CE. Antistreptococcal interventions for guttate and chronic plaque psoriasis. In: Cochrane Collaboration. Cochrane Library. Issue 2.Oxford: Update Software, 2000.

104. Chalmers RJ, O'Sullivan T, Owen CM, Griffiths CE. Interventions for guttate psoriasis. In: Cochrane Collaboration. Cochrane Library. Issue 2. Oxford: Update Software, 2000.

105. Hone SW, Donnelly MJ, Powell F, Blayney AW. Clearance of recalcitrant psoriasis after tonsillectomy. Clin Otolaryngol 1996;21:546-7.

106. Grimminger F, Mayser P, Papavassilis C et al. A doubleblind, randomized, placebo-controlled trial of n-3 fatty acid based lipid infusion in acute, extended guttate psoriasis. Rapid improvement of clinical manifestations and changes in neutrophil leukotriene profile. Clin Investigator 1993;71:634-43.

107. Vincent F, Ross JB, Dalton M, Wort AJ. A therapeutic trial of the use of penicillin V or erythromycin with or without rifampin in the treatment of psoriasis. J Am Acad Dermatol 1992;26:458-61.

108. Marsland AM, Murphy J, O'Sullivan T, Chalmers RJG, Griffiths CEM. Interventions for chronic palmoplantar pustular psoriasis. In: Cochrane Collaboration. Cochrane Library. Oxford: Update Software, submitted for publication 2002.

109. Erkko P, Granlund H, Remitz A et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998;139:997-1004.

110. Thomsen K. Pustulosis palmaris et plantaris treated with methotrexate. Acta Derm Venereol 1971;51:397-400.

Was this article helpful?

0 0
How To Prevent Skin Cancer

How To Prevent Skin Cancer

Complete Guide to Preventing Skin Cancer. We all know enough to fear the name, just as we do the words tumor and malignant. But apart from that, most of us know very little at all about cancer, especially skin cancer in itself. If I were to ask you to tell me about skin cancer right now, what would you say? Apart from the fact that its a cancer on the skin, that is.

Get My Free Ebook

Post a comment